Contents hide 1 About Pyrotinib 2 Approval 3 Dosage About Pyrotinib Irene (Pyrotinib) sold under the brand name 艾瑞妮 in china, Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours.  Approval Based on this phase II study, pyrotinib in combination with capecitabine received its first conditional approval in China for the treatment of HER2-positive, advanced or metastatic breast cancer previously exposed to anthracycline or taxane chemotherapy.  Dosage Depending on the indication, pyrotinib is taken orally at a standard dose of 400 mg/day. Dosage adjustments, combination, or non-combination of any antineoplastic agents are … Continue reading Irene (Pyrotinib)